Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

Group Schema Therapy for Borderline Personality Disorder.

- candidate number8183
- NTR NumberNTR2392
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR25-jun-2010
- Secondary IDsNL28016.068.09 / MEC 09-3-044 ; CCMO / medical ethical committee azM/UM
- Public TitleGroup Schema Therapy for Borderline Personality Disorder.
- Scientific TitleMulti-Site RCT of Group Schema Therapy for Borderline Personality Disorder.
- hypothesisGroup Schema Therapy is more effective and more cost-effective than treatment as usual for Borderline Personality Disorder.

Two subforms of group Schema Therapy (with different ratio of group and individual sessions) will also be compared, and stakeholders' opinions will be investigated (patients, therapists).
- Healt Condition(s) or Problem(s) studiedBorderline personality disorder
- Inclusion criteria1. Age 18-65 year;
2. Primary DSM-IV diagnosis of BPD (assessed with the SCID-II interview);
3. BPD severity above 20 on the BPDSI interview;
4. Willingness to participate in the study (informed consent procedure);
5. Ability to participate in (group) treatment and research for 2 years (e.g., no plans to move to other city).
- Exclusion criteria1. Lifetime psychotic disorder (short stress-related episodes are allowed, as described in DSM-IV BPD criterion 9);
2. IQ < 80 (in case of suspicion of low IQ, to be assessed with full intelligence test);
3. Unable to read, speak, or write the language used at the site (in case of suspicion an official language test is to be used);
4. ADHD (when suspected on basis of self-report for the KID-SCID is used to assess ADHD);
5. Bipolar disorder type 1 (SCID-1);
6. Dissociative Identity Disorder (confirmed by senior investigators);
7. Full or sub-threshold (defined as one less than the number of criteria to qualify for the diagnosis ) narcissistic or antisocial personality disorder (SCID-2);
8. Substance dependence needing clinical detox (after detox and 2 months sobriety can be included);
9. Serious and/or unstable medical illness;
10. Previous schema therapy of more than 3 months duration.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingSingle
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-feb-2010
- planned closingdate1-feb-2016
- Target number of participants448
- InterventionsExperimental A: 118 group Schema Therapy sessions over 2 years with max. 17 individual sessions.

Experimental B: 64 group Schema Therapy over 2 years with max. 61 individual sessions.

Control: Treatment as usual - the standard treatment given for that patient at the treatment center.
- Primary outcomeBorderline Personality Disorder Severity Index, mean score.
- Secondary outcome1. BPD-checklist, BSI, GAF, Work;
2. Social Adjustment Scale, Social Occupational Functioning Assessment Scale, Social Adjustment Scale-Self Report;
3. WHOQOL, EuroQol, Happiness Rating;
4. Schema questionnaire, Schema Mode Inventory, Group Climate Questionnaire (GCQ-S).
- TimepointsBaseline, 6,12,18, 24 months and 36 months.
- Trial web siteN/A
- statusopen: patient inclusion
- Sponsor/Initiator Maastricht University Medical Center (MUMC+)
- Funding
(Source(s) of Monetary or Material Support)
Dutch National Fund of Mental Health, Else-Kröner Fresenius Stiftung (Germany).
- PublicationsN/A
- Brief summaryIn an international multicenter RCT two forms of group Schema Therapy for Borderline Personality Disorder will be compared to the usual treatment provided to these patients. Effectiveness, cost-effectivenss (with full economic analysis, incl cost-utility and cost-effectiveness), and stakeholders'opnions will be assessed. A secondary aim is to find out what format of group Schema Therapy is to be preferred: mainly group treatment, or the combination of group and individual treatment. the study will take place in at least 14 centers in the Netherlands, Germany, USA, UK, Sweden, Ireland and Australia. At each center min. 32 participants will be recruited, and randomized over the two forms of group Schema Therapy and treatment as usual. Experimental treatment will be provided for 2 years, and a last follow-up assessment will be done at year 3.
- Main changes (audit trail)
- RECORD25-jun-2010 - 11-jul-2010

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar